Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

The Plaque Psoriasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key ...

The FDA has expanded the approval of Tremfya to include pediatric patients 6 years and older weighing at least 40kg for the treatment of moderate to severe plaque PsO and active PsA.

Anti-IL-17A biologics have the greatest odds of achieving and maintaining clear or almost clear skin among patients with psoriasis.

Genital psoriasis is common in psoriasis patients and shouldn't cause shame or interfere with your sex life, says ...

Pivoting to GLP-1 RAs, Soung explained that they both decrease appetite and food cravings and are very different from the weight loss drugs of the past in terms of how they work, the fact that they ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well ...

A 16-week Mediterranean diet intervention significantly improved psoriasis severity and metabolic health in adults with mild to moderate psoriasis. The study demonstrated a notable reduction in ...

Meditation, biofeedback, aromatherapy, and other such therapies can relieve stress caused by psoriasis and fend off stress-triggered flares.